Breadcrumb

[G18-12] Liposomal combination of cytarabine and daunorubicin (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-09-18 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Health Economics
Current document:PDF Dossier assessment  [PDF, 152 kB] (German version) Further documents
Note:

In accordance with § 35a (para. 1, sentence 11) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the cytarabine/daunorubicin report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.

Contact address:to the contact form

Report documents

Report documents

PublishedDocumentSizeType 
2019-01-02 Dossier assessment (German version) 152 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close